Ann: Volpara September Newsletter, page-36

I do believe a few things:
1. They overpaid for MRS
2. They underdelivered in sales growth
3. They overpromised on acquisitions
4. They put out a carrot of a density FDA paper approval which never ever occurs
5. They talk of capitalising on COVID-19 opportunities and deliver ZILCH
6. They dilute existing holders at will and squander cash like no tomorrow

Investors need endless patience in this overpriced healthcare company.